In a report released today, Brandon Couillard from Jefferies maintained a Buy rating on Bio-Rad Laboratories (NYSE: BIO), with a price target of $355. The company’s shares closed yesterday at $308.97, close to its 52-week high of $317.28.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of 27.9% and a 75.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Organovo Holdings, and Exact Sciences.
Bio-Rad Laboratories has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Bio-Rad Laboratories’ market cap is currently $9.21B and has a P/E ratio of 12.28. The company has a Price to Book ratio of 2.05.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments.
